-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $200

Benzinga·04/07/2026 14:24:01
Listen to the news
Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $164 to $200.